Download
the who prequalification of medicines programme dossier assessment update n.
Skip this Video
Loading SlideShow in 5 Seconds..
The WHO Prequalification of Medicines Programme Dossier Assessment Update PowerPoint Presentation
Download Presentation
The WHO Prequalification of Medicines Programme Dossier Assessment Update

The WHO Prequalification of Medicines Programme Dossier Assessment Update

230 Views Download Presentation
Download Presentation

The WHO Prequalification of Medicines Programme Dossier Assessment Update

- - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

  1. The WHO Prequalification of Medicines ProgrammeDossier Assessment Update Rutendo Kuwana Technical Officer Prequalification of Medicines Program WHO

  2. 5 Key Assessment Stages EMP TBS, 3 November 2011

  3. Invitation for Expression of interest (EOI) • A list of medicines invited for prequalification • Priority public health medicines • We can only accept product dossiers for medicines included in this list • List prepared by WHO clinical experts (HIV, TB, Malaria, RH, Influenza, Zinc, NTD) • Based on inclusion in treatment guidelines and/or WHO model list of essential medicines • Revised as needed to capture new developments EMP TBS, 3 November 2011

  4. Expressions of Interest Currently 8 EoIs • Active Pharmaceutical Ingredients (API) – 2nd • HIV/AIDS – 10th • Influenza – 2nd • Malaria – 9th • Neglected Tropical Diseases (NTD) – 1st • Reproductive Health – 5th • Tuberculosis – 10th • Diarrhoea (Zinc) – 1st EMP TBS, 3 November 2011

  5. Paths for inclusion of a product in the list of prequalified products • Prequalification of multisource generic products • Full review and inspection by PQP • Prequalification of innovators • Approval based on marketing authorization issued by an NMRA in ICH region and associated countries • Prequalification of generic products approved by SRA • Approval based on SRA marketing authorization • For established generic products • Recognition of temporary approvals / scientific opinions • USFDA PEPFAR approval/tentative approval • EMA article 58 • Health Canada Access programme EMP TBS, 3 November 2011

  6. Screening • Review data in the Application Form and Dossier • Mainly qualitative review i.e. is the data there or not • Some selected quantitative assessments done e.g. completeness of formulation tables, duration of studies • Administrative and Technical Completeness EMP TBS, 3 November 2011

  7. Product dossiers accepted for assessment: 2005 – 2011 (as at 1st November 2011) 20052006200720082009 20102011 HIV 67 42 25 42 24 21* 26(19) TB 17 9 17 12 11 16 17 (11) Malaria 3 5 7 9 3 6 8 (5) Repr Health - - 10 4 7 7 3 (0) Influenza - - - 1 7 0 0 (0) Diarrhoea - - - - 1 1 2 (1) NTD - - - - - - 1(1) Total Accptd 87 56 59 68 53 35 37 Total Submitted 90 92 83 51 57 * Includes 2 products (Water for Injection) not included in any of the EoIs (…) dossiers accepted for assessment EMP TBS, 3 November 2011

  8. Administration of assessments • Coordinator with a team of, • Quality assessors • BE assessors • Clinical assessors • Six full time (in-house) • More than 50 temporary advisors (pool of external assessors) • Six sessions per annum (every other month) in CPH. Details of meeting dates published on website • More than 30 assessors per session. EMP TBS, 3 November 2011

  9. 2005 – 2011 Prequalification Stats EMP TBS, 3 November 2011

  10. International standards for prequalification • Primarily WHO guidance documents and standards • PQ main generic and variation guidelines • The WHO Bioequivalence and bio waiver guidelines • The WHO Stability guideline • International Pharmacopoeia • WHO GMP and GCP Guidelines • ICH guidelines • Other guides issued by SRAs such as USFDA and EMA • Other recognized pharmacopoeias • BP, EP, JP, USP EMP TBS, 3 November 2011

  11. New guidelines EMP TBS, 3 November 2011 “Preparation” guideline: 10.375: Guideline on submission of documentation for a multisource (generic) finished pharmaceutical product (FPP): Preparation of product dossiers (PDs) in Common Technical Document (CTD) Format; “Quality” guideline: 10.373: Guideline on submission of documentation for a multisource (generic) finished pharmaceutical product (FPP): Quality part

  12. Key changes from the previous guideline EMP TBS, 3 November 2011 Reductions in requirements: - fewer batches required to establish the FPP shelf-life - process validation report for pilot batches no longer required (replaced by uniformity demonstration for the biolot) - reduced process validation/pharmaceutical development requirements for “established” generics

  13. Application of BCS in PQP • PQP has reviewed existing information on the bioavailability and dissolution data of the invited medicines • Identified some drug substances as eligible for a BCS-based biowaiver application - either monocomponent or fixed-dose combination (FDC) products • Monocomponent or FDC products containing other drug substances must be supported with in vivo BE data EMP TBS, 3 November 2011

  14. PQ Dossier Variation Guidance Three main categories of variations, according to potential impact to quality of product and current timelines we aim to achieve (achieved already) • Notification - no or minimal impact: 30 days • Minor change - potential minor impact: 60 days • Major change - potential major impact: 60 days EMP TBS, 3 November 2011

  15. Requalification Procedure for prequalification of pharmaceutical products requires holders of WHO-prequalified products to submit a quality review after five years from the date of prequalification of the product, or when requested to do so by PQP (whichever date is earlier) EMP TBS, 3 November 2011

  16. Status of RQ Applications – Oct 2011 EMP TBS, 3 November 2011

  17. Current Affairs • Revision of the Variation Guidelines • Published list of prequalified APIs and their specific attributes (5) • Part 2(b) of WHOPAR including pictures of product • Part 8 of WHOPAR – variations now included • Publish prevailing timelines for key processes • New internal centralised and enhanced database • Information to applicants on how we prioritise assessments and inspections • BCS biowaiver – to include Emtricitabine and Abacavir EMP TBS, 3 November 2011